Loading...
•
Sep 30, 2020
Tandem Diabetes Q3 2020 Earnings Report
Reported financial results for the third quarter of 2020 and updated its sales guidance for the year ending December 31, 2020.
Key Takeaways
Tandem Diabetes Care reported a 31% increase in sales to $123.6 million and an improved operating margin of negative 1 percent in Q3 2020. Worldwide pump shipments increased 23 percent to 22,021 pumps.
Worldwide pump shipments increased 23 percent to 22,021 pumps.
Sales increased 31 percent to $123.6 million.
Operating margin improved to negative 1 percent.
Domestic pump shipments increased 33 percent to 18,380 pumps.
Tandem Diabetes
Tandem Diabetes
Tandem Diabetes Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.comOutside the United States Revenue
CapyFin.com Forward Guidance
The Company is updating its sales guidance estimated to be in the range of $465 million to $475 million, which includes international sales of approximately $70 million to $75 million for the year ending December 31, 2020.
Positive Outlook
- Sales guidance estimated to be in the range of $465 million to $475 million.
- International sales of approximately $70 million to $75 million.
- Annual sales growth of 28 percent to 31 percent compared to 2019.
Revenue & Expenses
Visualization of income flow from segment revenue to net income